- Obstructive sleep apnea affects millions of people of all ages. It is estimated that OSA costs the US economy $165B annually. The Vivos technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated hundreds of millions of people globally who suffer from OSA.
- As dentists have hundreds of patients of all ages suffering from OSA, the Vivos System presents a multi-million dollar revenue opportunity for dental practices.
- Vivos is helping address challenges throughout the world, reducing the overall cost of health care by focusing on a prevalent condition which is linked to many of the most expensive health care problems.
- The Vivos System is thought to be the most significant breakthrough in OSA treatment since CPAP.
- The system’s treatment time is a fraction of that of its alternatives—patients can find lasting relief in a matter of months, eliminating the need for surgery or a lifetime of therapy.
- Vivos® Integrated Practices are supported by a network of clinical, practice and market advisors who provide guidance, collaboration, various capacities of coaching, and market intelligence in support of growth and distribution.
Headquartered in Denver, Colorado, Vivos Therapeutics Inc. is an emerging global leader in the treatment of obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.
At the core of Vivos’ mission to eradicate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health care providers.
In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the U.S., Canada and Asia.
Market & Technology Overview
Craniofacial developmental deficiencies, such as underdeveloped upper and lower jaws, are the leading cause of OSA. According to a 2019 analysis from researchers at the University of California, San Diego, an estimated 81 million adults in North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients, with approximately 54 million adults affected, according to the report.
Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated hundreds of millions of people globally who suffer from OSA.
Vivos integrates its specially designed, customized appliances into a patient-specific, multi-disciplinary clinical protocol, giving trained dental and medical providers the tools and roadmap needed to address certain craniofacial conditions that have proven to be associated with sleep-disordered breathing—including OSA.
The system’s treatment protocol involves collaboration between physicians, specially trained dentists who have received advanced training in craniofacial sleep medicine, and additional health care providers. Vivos-trained clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,350 trained dentists.
A New Paradigm in Sleep Medicine
Vivos’ proprietary system poses the potential to be the biggest breakthrough in OSA treatment since CPAP.
Designed to promote correct growth and development of the hard and soft tissues surrounding and compromising the oral cavity, nasal cavity, upper and lower jaws, and other tissues which comprise and shape the human airway. The system uses Pneumopedics®, the natural process induced by Vivos biomimetic technology to widen and expand the patient’s airway, allowing for proper breathing through the nose, effectively addressing the root cause of OSA.
This patented technology offers benefits over CPAP and other oral appliances in its ability to achieve results relatively quickly—in about 18 to 24 months or less—at a lower cost, and without the need for lifetime intervention in most patients. It is believed to be the first effective, non-surgical, non-invasive and potentially long-lasting solution to eradicating OSA.
A cooperative agreement with Benco Dental, the largest family-owned dental distributor in the United States, broadens the reach of the Vivo System. This partnership ensures that all dentists in the United States have access to Vivo’s patented system, on par with Vivo’s vision to provide clinicians with the tools to provide the best alternative solution to treat OSA and well-aligned with Benco’s commitment to evolve the dentistry industry by empowering clinicians with innovative treatment options.
- Kirk Huntsman – CEO, Director
With experience in strategic development, technology acquisition and product planning, key talent recruitment, and target market prioritization, Huntsman brings a broad vision paired with leadership and strategic planning skills. He has significant start-up experience in a diverse range of market sectors, including medical devices, dental management, dental practice valuations and transitions, multi-location retail, financial and capital formation, consulting, outsourced services, imports and exports (China), medical services, and software and technology.
Dr. Dave Singh – Founder, Director
A doctor three times over in dental medicine, craniofacial development, and orthodontics, Dr. Singh was educated primarily in England and has lectured in North America, Europe, Asia, and Africa. The Global Summits Institute recently named Dr. Singh as one of the Top 100 Doctors in Dentistry.
For more information, visit the company’s website at www.VivosLife.com
NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.